Genmab A/S (NASDAQ:GMAB) ranks among the best high growth European stocks to buy. On January 20, H.C. Wainwright cut its price target for Genmab A/S (NASDAQ:GMAB) to $39 from $41, retaining a Buy rating on the company’s shares. The change comes after Genmab and partner AbbVie announced that their Phase 3 EPCORE DLBCL-1 trial found no meaningful improvement in the overall survival for EPKINLY (epcoritamab) monotherapy when compared to standard treatments in second-line diffuse large B-cell lymphoma (DLBCL) ...

Group 1 - Genmab A/S is recognized as one of the top oncology stocks to buy, with Deutsche Bank raising its price target for GMAB to DKK 2,400 from DKK 2,000 and maintaining a Buy rating, indicating strong analyst optimism regarding the company's late-stage oncology pipeline [1][3] - The company has partnered with AI research firm Anthropic to enhance its R&D capabilities through the use of agentic AI powered by Claude models, aiming for a more scalable and effective R&D process while maintaining human oversight [2] - Genmab specializes in developing innovative antibody-based therapies for cancer treatment, with its late-stage pipeline featuring promising programs such as Rina-S and Epkinly [3]

Industry Overview - The oncology market in the United States is projected to grow from an estimated $81.34 billion in 2025 to $211.78 billion by 2034, reflecting a compound annual growth rate (CAGR) of 11.75% driven by rising cancer rates and demand for personalized treatments [1] - Targeted treatments and monoclonal antibodies are leading sectors, with monoclonal antibodies expected to account for approximately 30% of market sales in 2024 [2] - Major trends include the integration of artificial intelligence (AI) in predicting patient responses to immunotherapy, with expected accuracy rates of 70%-80% by 2026 [3] Emerging Technologies - The oncology field is increasingly focusing on molecularly defined subsets of cancer, allowing for targeted therapies based on specific mutations rather than organ sites [4] - Therapeutic messenger RNA (mRNA) vaccines are in late-stage clinical trials, with potential approval anticipated between 2027 and 2029 [4] - Innovations such as Antibody-Drug Conjugates (ADCs), Bi-specific T-cell Engagers (TCEs), and non-invasive liquid biopsies are enhancing treatment efficacy and monitoring techniques [3][4] Company Highlights - Genmab A/S (NASDAQ:GMAB) is recognized for its innovative antibody-based therapies and has a promising late-stage oncology pipeline, including programs like Rina‑S and Epkinly [10][12] - Novartis AG (NYSE:NVS) has a robust oncology portfolio with over 30 high-value therapies and is investing in precision oncology and advanced manufacturing, including a new RLT facility in Florida as part of a $23 billion U.S. investment strategy [13][14][15]